SCORE2-CKD

1 paper2 findings

Humans1

Interventions

1

SGLT2 inhibitors

upin humans1downin humans1

1 study

SGLT2 inhibitors increase SCORE2-CKD in humans (Δ + 3.25, P = .044).
Humansin CKD patients without diabetes12 months
Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes
Journal of nephrology12 Aug 2026
SGLT2 inhibitors decrease SCORE2-CKD in humans (Δ -3.85, 95% CI -4.35 to -3.35, P = .023).
Humansin CKD patients with type 2 diabetes12 months
Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes
Journal of nephrology12 Aug 2026

More on SGLT2 inhibitors

Latest

1 in 12 months

Journal of Nephrology13 Aug

Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes

Cohort study of 132 peopleSGLT2 inhibitors